SI1082129T1 - Method for the treatment of fertility disorders - Google Patents

Method for the treatment of fertility disorders

Info

Publication number
SI1082129T1
SI1082129T1 SI9930448T SI9930448T SI1082129T1 SI 1082129 T1 SI1082129 T1 SI 1082129T1 SI 9930448 T SI9930448 T SI 9930448T SI 9930448 T SI9930448 T SI 9930448T SI 1082129 T1 SI1082129 T1 SI 1082129T1
Authority
SI
Slovenia
Prior art keywords
treatment
fertility disorders
antagonists
fertility
disorders
Prior art date
Application number
SI9930448T
Other languages
English (en)
Slovenian (sl)
Inventor
J�Rgen Engel
Hilde Riethm�Ller-Winzen
Thomas Reissmann
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of SI1082129T1 publication Critical patent/SI1082129T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9930448T 1998-04-23 1999-03-29 Method for the treatment of fertility disorders SI1082129T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8274398P 1998-04-23 1998-04-23
PCT/EP1999/002133 WO1999055357A1 (en) 1998-04-23 1999-03-29 Method for the treatment of fertility disorders

Publications (1)

Publication Number Publication Date
SI1082129T1 true SI1082129T1 (en) 2004-02-29

Family

ID=22173160

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930448T SI1082129T1 (en) 1998-04-23 1999-03-29 Method for the treatment of fertility disorders

Country Status (24)

Country Link
US (1) US6319192B1 (xx)
EP (1) EP1082129B1 (xx)
JP (1) JP2002512975A (xx)
KR (1) KR100632722B1 (xx)
AT (1) ATE252910T1 (xx)
AU (1) AU752415B2 (xx)
BR (1) BR9909802A (xx)
CA (1) CA2330131C (xx)
CZ (1) CZ301912B6 (xx)
DE (1) DE69912422T2 (xx)
DK (1) DK1082129T3 (xx)
ES (1) ES2207941T3 (xx)
HU (1) HU228736B1 (xx)
IL (1) IL139027A0 (xx)
NO (1) NO326406B1 (xx)
NZ (1) NZ507405A (xx)
PL (1) PL195989B1 (xx)
PT (1) PT1082129E (xx)
RU (1) RU2221588C2 (xx)
SI (1) SI1082129T1 (xx)
SK (1) SK285192B6 (xx)
TR (1) TR200003063T2 (xx)
UA (1) UA66850C2 (xx)
WO (1) WO1999055357A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
EP0788799A3 (en) * 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
US8173592B1 (en) * 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
US8465412B2 (en) * 2001-01-12 2013-06-18 Michael Levy Uterine devices and method of use
US6758806B2 (en) 2001-01-12 2004-07-06 Napoli, Llc Endoscopic devices and method of use
US6623422B2 (en) * 2001-01-12 2003-09-23 Napoli, Llc Method and apparatus for assisted embryo implantation
US20060183973A1 (en) * 2001-01-12 2006-08-17 Kamrava Michael M Endoscopic devices and method of use
CN1313059C (zh) * 2001-01-12 2007-05-02 纳波利有限公司 一种用于内窥镜下胚胎移植的微型导液管
WO2003051344A1 (en) * 2001-12-14 2003-06-26 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation_using a non-polypeptide camp level modulator
US7033314B2 (en) * 2002-01-11 2006-04-25 Fidelitycorp Limited Endoscopic devices and method of use
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
US6695766B2 (en) 2002-04-26 2004-02-24 Olympia Womens Health Magnetic embryo transfer
EP1364658A1 (en) * 2002-05-24 2003-11-26 Applied Research Systems ARS Holding N.V. Use of varying ratios of gonadotrophins in controlled ovarian hyperstimulation
MXPA04012246A (es) 2002-06-07 2005-04-08 Ares Trading Sa Metodo para la hiperestimulacion ovarica controlada y equipo farmaceutico para usarlo en dicho metodo.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
DE4305225A1 (de) 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
EP0788799A3 (en) * 1996-02-07 1998-10-21 ASTA Medica Aktiengesellschaft LHRH-Antagonists in the treatment of fertility disorders
US5824548A (en) * 1996-05-29 1998-10-20 Wisconsin Alumni Research Foundation Method of increasing survival of cultured primate embryos in medium containing exogenous gonadotrophin releasor hormone
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US5961444A (en) * 1997-10-17 1999-10-05 Medworks Corporation In vitro fertilization procedure using direct vision

Also Published As

Publication number Publication date
IL139027A0 (en) 2001-11-25
DE69912422D1 (de) 2003-12-04
EP1082129B1 (en) 2003-10-29
HUP0101528A3 (en) 2001-12-28
KR20010042873A (ko) 2001-05-25
WO1999055357A1 (en) 1999-11-04
KR100632722B1 (ko) 2006-10-16
DK1082129T3 (da) 2004-01-26
EP1082129A1 (en) 2001-03-14
CZ20003766A3 (cs) 2001-08-15
TR200003063T2 (tr) 2001-02-21
NO326406B1 (no) 2008-11-24
PT1082129E (pt) 2004-03-31
HU228736B1 (en) 2013-05-28
NO20005145D0 (no) 2000-10-13
NZ507405A (en) 2002-10-25
AU752415B2 (en) 2002-09-19
PL195989B1 (pl) 2007-11-30
CZ301912B6 (cs) 2010-07-28
ATE252910T1 (de) 2003-11-15
SK285192B6 (sk) 2006-08-03
ES2207941T3 (es) 2004-06-01
AU3702899A (en) 1999-11-16
SK15302000A3 (sk) 2001-10-08
PL343609A1 (en) 2001-08-27
NO20005145L (no) 2000-10-13
DE69912422T2 (de) 2004-08-19
US6319192B1 (en) 2001-11-20
BR9909802A (pt) 2000-12-26
CA2330131A1 (en) 1999-11-04
HUP0101528A2 (hu) 2001-11-28
JP2002512975A (ja) 2002-05-08
UA66850C2 (uk) 2004-06-15
RU2221588C2 (ru) 2004-01-20
CA2330131C (en) 2011-10-25

Similar Documents

Publication Publication Date Title
PL343609A1 (en) Method for the treatment of fertility disorders
LT96133A (en) Remedy for treatment of ovarian estrogen dependent conditions
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
MXPA04004364A (es) Composiciones para el tratamiento de disfuncion sexual femenina postmenopausica.
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
ATE114116T1 (de) Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel.
BG101553A (en) Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives
HUP9902076A2 (hu) Szexuális rendellenességek kezelésére alkalmas intranazális készítmény
HUT77966A (hu) II.Típusú ösztrogénreceptor antagonista hatású flavanolignánokat tartalmazó antiproliferatív hatású gyógyszerkészítmények és azok előállítása
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
ES8207511A1 (es) Un procedimiento para la preparacion de nuevos peptidos.
PT1066304E (pt) Antagonistas macrolidos de lhrh
NZ506622A (en) 3',3'-N-bis-substituted macrolide LHRH antagonists
BRPI0409571A (pt) métodos e kits para a manutenção de gravidez, tratamento de cistos foliculares, e sincronização da ovulação empregando-se hormÈnio de luteinização
EP0788799A3 (en) LHRH-Antagonists in the treatment of fertility disorders
WO2001021194A3 (en) Method for the therapeutic management of endometriosis and fallopian tube obstruction
EP0268066A3 (en) Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
Nillius et al. A new superagonist of GnRH for inhibition of ovulation in women
ATE215834T1 (de) Ovulation auslösende arzneistoffe enthaltend luteinisierendes hormon
Yoro Anatomical Approach to Human Thinking
MX9707008A (es) Uso de antiestrogenos para control natal en hombres.